Literature DB >> 27020041

Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice.

Adam L Halberstadt1, Ivan S Sindhunata2, Kees Scheffers2, Aaron D Flynn2, Richard F Sharp2, Mark A Geyer3, Jared W Young3.   

Abstract

Timing deficits are observed in patients with schizophrenia. Serotonergic hallucinogens can also alter the subjective experience of time. Characterizing the mechanism through which the serotonergic system regulates timing will increase our understanding of the linkage between serotonin (5-HT) and schizophrenia, and will provide insight into the mechanism of action of hallucinogens. We investigated whether interval timing in mice is altered by hallucinogens and other 5-HT2 receptor ligands. C57BL/6J mice were trained to perform a discrete-trials temporal discrimination task. In the discrete-trials task, mice were presented with two levers after a variable interval. Responding on lever A was reinforced if the interval was <6.5 s, and responding on lever B was reinforced if the interval was >6.5 s. A 2-parameter logistic function was fitted to the proportional choice for lever B (%B responding), yielding estimates of the indifference point (T50) and the Weber fraction (a measure of timing precision). The 5-HT2A antagonist M100907 increased T50, whereas the 5-HT2C antagonist SB-242,084 reduced T50. The results indicate that 5-HT2A and 5-HT2C receptors have countervailing effects on the speed of the internal pacemaker. The hallucinogen 2,5-dimethoxy-4-iodoamphetamine (DOI; 3 mg/kg IP), a 5-HT2 agonist, flattened the response curve at long stimulus intervals and shifted it to the right, causing both T50 and the Weber fraction to increase. The effect of DOI was antagonized by M100907 (0.03 mg/kg SC) but was unaffected by SB-242,084 (0.1 mg/kg SC). Similar to DOI, the selective 5-HT2A agonist 25CN-NBOH (6 mg/kg SC) reduced %B responding at long stimulus intervals, and increased T50 and the Weber fraction. These results demonstrate that hallucinogens alter temporal perception in mice, effects that are mediated by the 5-HT2A receptor. It appears that 5-HT regulates temporal perception, suggesting that altered serotonergic signaling may contribute to the timing deficits observed in schizophrenia and other psychiatric disorders.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Discrete-trials; Hallucinogen; Interval timing; Mice; Psychedelic

Mesh:

Substances:

Year:  2016        PMID: 27020041      PMCID: PMC5403251          DOI: 10.1016/j.neuropharm.2016.03.038

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  90 in total

1.  The physiological role of 5-HT2A receptors in working memory.

Authors:  Graham V Williams; Srinivas G Rao; Patricia S Goldman-Rakic
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

2.  Serotonin (5-hydroxytryptamine) 5-HT(2A) receptor: association with inherent and cocaine-evoked behavioral disinhibition in rats.

Authors:  Noelle C Anastasio; Erin C Stoffel; Robert G Fox; Marcy J Bubar; Kenner C Rice; Frederick G Moeller; Kathryn A Cunningham
Journal:  Behav Pharmacol       Date:  2011-06       Impact factor: 2.293

3.  Effects of varied doses of psilocybin on time interval reproduction in human subjects.

Authors:  Jirí Wackermann; Marc Wittmann; Felix Hasler; Franz X Vollenweider
Journal:  Neurosci Lett       Date:  2008-02-09       Impact factor: 3.046

4.  Timing dysfunctions in schizophrenia as measured by a repetitive finger tapping task.

Authors:  Christine A Carroll; Brian F O'Donnell; Anantha Shekhar; William P Hetrick
Journal:  Brain Cogn       Date:  2009-08-06       Impact factor: 2.310

5.  Temporal processing in schizophrenia: effects of task-difficulty on behavioral discrimination and neuronal responses.

Authors:  Deana B Davalos; Donald C Rojas; Jason R Tregellas
Journal:  Schizophr Res       Date:  2010-08-01       Impact factor: 4.939

6.  Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT1A and 5-HT2A receptors.

Authors:  M Victoria Puig; Akiya Watakabe; Mika Ushimaru; Tetsuo Yamamori; Yasuo Kawaguchi
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

7.  SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system.

Authors:  V Di Matteo; G Di Giovanni; M Di Mascio; E Esposito
Journal:  Neuropharmacology       Date:  1999-08       Impact factor: 5.250

8.  Timing dysfunctions in schizophrenia span from millisecond to several-second durations.

Authors:  Christine A Carroll; Brian F O'Donnell; Anantha Shekhar; William P Hetrick
Journal:  Brain Cogn       Date:  2009-03-17       Impact factor: 2.310

9.  Effects of methamphetamine on duration discrimination.

Authors:  Münire Ozlem Cevik
Journal:  Behav Neurosci       Date:  2003-08       Impact factor: 1.912

Review 10.  Serotonin research: contributions to understanding psychoses.

Authors:  Mark A Geyer; Franz X Vollenweider
Journal:  Trends Pharmacol Sci       Date:  2008-09       Impact factor: 14.819

View more
  18 in total

1.  Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.

Authors:  Adam L Halberstadt; Jochem V F van der Zee; Muhammad Chatha; Mark A Geyer; Susan B Powell
Journal:  Psychopharmacology (Berl)       Date:  2018-11-17       Impact factor: 4.530

2.  Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor.

Authors:  Kuglae Kim; Tao Che; Ouliana Panova; Jeffrey F DiBerto; Jiankun Lyu; Brian E Krumm; Daniel Wacker; Michael J Robertson; Alpay B Seven; David E Nichols; Brian K Shoichet; Georgios Skiniotis; Bryan L Roth
Journal:  Cell       Date:  2020-09-17       Impact factor: 41.582

3.  Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges.

Authors:  Zackary A Cope; Adam L Halberstadt; Jordy van Enkhuizen; Aaron D Flynn; Michelle Breier; Neal R Swerdlow; Mark A Geyer; Jared W Young
Journal:  Psychopharmacology (Berl)       Date:  2016-08-17       Impact factor: 4.530

Review 4.  Effect of Hallucinogens on Unconditioned Behavior.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2018

5.  Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice.

Authors:  Adam L Halberstadt; Muhammad Chatha; Stephen J Chapman; Simon D Brandt
Journal:  J Psychopharmacol       Date:  2019-02-21       Impact factor: 4.153

6.  Serotonin 1B receptor effects on response inhibition are independent of inhibitory learning.

Authors:  Stephanie S Desrochers; Katherine M Nautiyal
Journal:  Neurobiol Learn Mem       Date:  2021-12-12       Impact factor: 2.877

7.  Sex-specific role for serotonin 5-HT2A receptor in modulation of opioid-induced antinociception and reward in mice.

Authors:  Salvador Sierra; Karan H Muchhala; Donald K Jessup; Katherine M Contreras; Urjita H Shah; David L Stevens; Jennifer Jimenez; Xiomara K Cuno Lavilla; Mario de la Fuente Revenga; Kumiko M Lippold; Shanwei Shen; Justin L Poklis; Liya Y Qiao; William L Dewey; Hamid I Akbarali; M Imad Damaj; Javier González-Maeso
Journal:  Neuropharmacology       Date:  2022-02-17       Impact factor: 5.273

8.  DARK Classics in Chemical Neuroscience: NBOMes.

Authors:  Christian B M Poulie; Anders A Jensen; Adam L Halberstadt; Jesper L Kristensen
Journal:  ACS Chem Neurosci       Date:  2019-11-12       Impact factor: 5.780

9.  Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; Jason Wallach; Simon D Brandt
Journal:  Neuropharmacology       Date:  2020-01-07       Impact factor: 5.273

10.  Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; John D McCorvy; Markus R Meyer; Lea Wagmann; Alexander Stratford; Simon D Brandt
Journal:  Neuropharmacology       Date:  2019-11-19       Impact factor: 5.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.